In 1999, Dr Christopher Tsai entered the new field of stem cells and genomics with Bionet, and found a commercial niche in cord blood banking. He came to realise that the future of the company lay in personalised medicine services for individual customers, and in 2006 Tsai formed a separate company, GGA, dedicated to genetic testing and diagnoses.

Bionet and GGA have provided stem cells, genetic testing, anti-ageing skin care product and cell therapy to over 1.4 million customers, from babies to adults, in 17 countries. As research into mesenchymal stem cell applications was ramped up during the pandemic, Tsai’s established MSC bank has been able to offer a stable supply of umbilical cord-MSC units for the treatment of Covid-19, along with acute respiratory distress syndrome (ARDS), lung fibrosis and others.

In 2022, TCI established Xunlian Cell Intelligent Medicine Co., Ltd. to accelerate the development of regenerative medicine and exosomal therapy and provide a wider range of services.